Setrobuvir

Setrobuvir
Names

IUPAC name N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ⁶,2,4-benzothiadiazin-7-yl)methanesulfonamide
Other names ANA-598; ANA598
Identifiers
CAS Number	1214735-09-7^N 1071517-39-9^Y
3D model (Jmol)	Interactive image
ChEMBL	ChEMBL1076263^Y
ChemSpider	24680206^Y
KEGG	D10165^N
PubChem	45136829
InChI InChI=1S/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1^Y Key: DEKOYVOWOVJMPM-RLHIPHHXSA-N^Y InChI=1/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1 Key: DEKOYVOWOVJMPM-RLHIPHHXBY
SMILES CS(NC(C=C1)=CC2=C1NC(C3=C(O)[C@@]4([H])[C@@]([C@@H]5CC[C@H]4C5)([H])N(CC6=CC=C(F)C=C6)C3=O)=NS2(=O)=O)(=O)=O
Properties
Chemical formula	C₂₅H₂₅FN₄O₆S₂
Molar mass	560.62 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is ^YN ?)
Infobox references

Setrobuvir (INN,^[1] USAN,^[2] also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir.^[3] It was in Phase IIb clinical trials, used in combination with interferon and ribavirin,^[4] targeting hepatitis C patients with genotype 1.^[3]

Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.^[5]

Its development was discontinued on July 15, 2015.^[6]

References

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 68" (PDF). World Health Organization. p. 322.
↑ Statement on a Nonproprietary Name Adopted by the USAN Council
1 2 "HCV Followup: Anadys Acquired for Active Antiviral". Central Science, Chemical & Engineering News. October 24, 2011.
↑ "Roche-Anadys Hookup Could Spark More Hep C Acquisitions". TheStreet.com. October 17, 2011.
↑ Ruebsam, F; Murphy, DE; Tran, CV; Li, LS; Zhao, J; Dragovich, PS; McGuire, HM; Xiang, AX; et al. (2009). "Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase". Bioorganic & Medicinal Chemistry Letters. 19 (22): 6404–12. doi:10.1016/j.bmcl.2009.09.045. PMID 19818610.
↑ "Setrobuvir — UKMi New Drugs Online Database". UKMi Medicines Information.

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Faldaprevir^‡ Grazoprevir Paritaprevir Simeprevir Telaprevir

NS5A inhibitors (–asvir)	Daclatasvir Elbasvir Ledipasvir MK-3682 MK-8408 Odalasvir^† Ombitasvir Ravidasvir^† Samatasvir^† Velpatasvir

NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Dasabuvir Deleobuvir^§ Filibuvir^§ Setrobuvir^§ Sofosbuvir Radalbuvir^†

Combination drugs	Elbasvir/grazoprevir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Velpatasvir/sofosbuvir

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Umifenovir

neuraminidase inhibitors/release phase (Oseltamivir
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^#

Multiple/unknown	BCX4430^† Favipiravir GS-5734^† Mericitabine^† MK-608^§ NITD008^§ Moroxydine Ribavirin^#/Taribavirin^† Triazavirin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 12/7/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.